Identification of a novel PPARγ modulator with good anti-diabetic therapeutic index via structure-based screening, optimization and biological validation
PPARγ is well-known as the target receptor of TZD anti-diabetic drugs. However, recently the therapeutic benefits of these TZD drugs have been compromised by many severe side effects because of their full PPARγ agonistic action to lock the AF-2 helix. Herein, we conducted a virtual screening in the...
Main Authors: | Fangyuan Chen, Lei Ma, Guihui Cai, Junyuan Tang, Yi Wang, Qingmei Liu, Xiawen Liu, Ning Hou, Zhi Zhou, Wei Yi |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-10-01
|
Series: | Biomedicine & Pharmacotherapy |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0753332222010423 |
Similar Items
-
PPM1A Controls Diabetic Gene Programming through Directly Dephosphorylating PPARγ at Ser273
by: Keon Woo Khim, et al.
Published: (2020-02-01) -
Biological Screening and Crystallographic Studies of Hydroxy γ-Lactone Derivatives to Investigate PPARγ Phosphorylation Inhibition
by: Davide Capelli, et al.
Published: (2023-04-01) -
Pharmacological (or Synthetic) and Nutritional Agonists of PPAR-γ as Candidates for Cytokine Storm Modulation in COVID-19 Disease
by: Carmen Ciavarella, et al.
Published: (2020-04-01) -
Dysregulation of the Amniotic PPARγ Pathway by Phthalates: Modulation of the Anti-Inflammatory Activity of PPARγ in Human Fetal Membranes
by: Audrey Antoine, et al.
Published: (2022-04-01) -
The Potential for Placental Activation of PPARγ to Improve the Angiogenic Profile in Preeclampsia
by: Brooke Grimaldi, et al.
Published: (2022-11-01)